leisure time -WSS

leisure time

author：focus 2025-09-30 18:20:42 - browse：112

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： The high personal cost of affirmative action for Black doctors

WSS

Eli Lilly to pay $200M for Beam’s stake in gene

Traditional Chinese medicine benefits explored in new JAMA study

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

No plane should take off without an EpiPen onboard

What the US credit downgrade means for the economy, your finances

Senate panel to vote on hospitals, PBMs, prisoner care

entertainment

leisure time

leisure time

Sports medicine is finally prioritizing gender equality

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Medicare details structure of new drug price negotiation program

Mitch McConnell episode has important public health takeaway

Bright Health sells Medicare Advantage business to Molina

Physician subsidies by hospitals soar in wake of No Surprises Act

In Memoriam: Notable people who died in 2023

Testing for cancer recurrence creates a new limbo for patients

Medical leaders decry Supreme Court decision on affirmative action

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

focus

Diversifying clinical trials isn't enough to close racial gaps: study

Sage hopes for a blockbuster in antidepressant now before FDA

Mitch McConnell episode has important public health takeaway

Emergency medicine has repudiated 'excited delirium.' Now what?

Cassava reveals details — and problems — with Alzheimer's study

The FDA weighs the risks of candy

hotspot

focus

focus

Wikipedia